Table 2.

Comparison of LV remodeling and function by CMR, before (Baseline) and 28 days after induction of experimental autoimmune myocarditis, following 20 days of daily IP injection of cromolyn sodium or saline

	Cromolyn (n=7)	Control (n=5)	P for treatment effect
LV wall thickness, mm
Baseline	2.5±0.08	2.5±0.08	0.63
28 days	2.7±0.16	2.8±0.22
P	0.32	0.46
LVDA, mm2
Baseline	36±2	34±3
28 days	43±3	45±3	0.97
P	0.02	0.01
LVSA, mm2
Baseline	9±1	9±0.9
28 days	13±2	18±2	0.12
P	0.03	0.005
LV mass, mg
Baseline	437±24	453±38
28 days	501±34	480±43	0.95
P	0.19	0.65
EDV, μL
Baseline	306±22	301±34
28 days	417±29	451±32	0.68
P	<0.001	0.04
ESV, μL
Baseline	116±9	114±10
28 days	226±20	277±29
P	0.001	0.007
SV, μL
Baseline	190±17	187±25
28 days	191±27	174±6	0.67
P	0.96	0.61
EF, %
Baseline	62±2	62±2
28 days	45±5	39±3	0.35
P	0.03	0.001

^aValues are means ± SE.

^bP values in the left columns are for the differences between baseline and 28-days measurements. P values in the right column reflect comparison of the differences between treatment and control groups over time (see Methods).

^cLV = left ventricular; LVDA = LV end diastolic area; LVSA = LV end systolic area; EDV = end diastolic volume; ESV= end systolic volume; SV= stroke volume = EDV – ESV; EF = ejection fraction =[(EDV (−) ESV)/EDV]×100.